PT - JOURNAL ARTICLE AU - Kleyner, Robert AU - Mohammad, Arif AU - Marchi, Elaine AU - Horowitz, Naomi AU - Haworth, Andrea AU - King, Brian AU - Gavin, Maureen AU - Amble, Karen AU - Velinov, Milen AU - Lyon, Gholson J. TI - Autosomal recessive <em>SLC30A9</em> Mutations in a Proband with a Cerebro-Renal Syndrome and No Parental Consanguinity AID - 10.1101/2021.07.21.21260807 DP - 2021 Jan 01 TA - medRxiv PG - 2021.07.21.21260807 4099 - http://medrxiv.org/content/early/2021/07/22/2021.07.21.21260807.short 4100 - http://medrxiv.org/content/early/2021/07/22/2021.07.21.21260807.full AB - An SLC30A9-associated cerebro-renal syndrome was first reported in consanguineous Bedouin kindred by Perez et al. in 2017. While the function of the gene has not yet been fully elucidated, it may be implicated in Wnt signaling, nuclear regulation, as well as cell and mitochondrial zinc regulation. In this research report, we present a female proband with two distinct, inherited autosomal recessive loss-of-function SLC30A9 variants from unrelated parents. To our knowledge, this is the first reported case of a possible SLC30A9-associated cerebro-renal syndrome in a non-consanguineous family. Furthermore, a limited statistical analysis was conducted to identify possible allele frequency differences between populations. Our findings provide further support for an SLC30A9-associated cerebro-renal syndrome and may help further clarify the gene’s function.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo external funding was received for this work.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This was approved as per below by the New York State Psychiatric Institute IRB. Protocol Number: 7659 Version Date:02/05/2021 Protocol Title: Genomic and Metabolic Identification of previously unknown mutations for Intellectual and Developmental Disabilities and/or AutismAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data that support the findings of this study are available on request from the corresponding author. The data are not publicly available due to privacy or ethical restrictions.